The F-3 caps the Wainwright ATM at $824,331 because the public float is below $75.0 million. The filing puts the float at $4.9 million, and the ADS last traded at $3.78 on May 18, 2026.
The ADSs held a closing bid of $1.00 or more for at least 10 consecutive business days, reached on March 13, 2026. The company is now compliant with applicable listing standards.
The August filing assumed $2.22 per ADS. The September 4 pricing set a combined $1.00 with short-term warrants, for about $6 million of gross proceeds before fees.
Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.
Questions about Purple Biotech
Has Purple Biotech raised money recently?
Our latest story on this, dated May 20, 2026: "Purple Biotech files $200,000,000 replacement shelf, ATM limited to $824,331". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Purple Biotech?
Purple Biotech Ltd. trades under the ticker PPBT on TASE.
Where is Purple Biotech listed?
Purple Biotech Ltd. is listed on TASE. Our directory also records these other listings: NASDAQ:PPBT.
What is the SEC CIK of Purple Biotech?
The SEC Central Index Key (CIK) for Purple Biotech Ltd. is 1614744. Its filings are on SEC EDGAR.
How many shares does Purple Biotech have outstanding?
1,858,911,801 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-03-19.
Which country or territory is Purple Biotech listed under?
Our directory records Purple Biotech Ltd. under Israel.
What does Purple Biotech do?
Our directory classifies Purple Biotech Ltd. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Purple Biotech?
The ISIN recorded for Purple Biotech Ltd. is IL0007650166.
Does aibio.space cover Purple Biotech?
aibio.space lists Purple Biotech Ltd. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Purple Biotech incorporated?
SEC records list its state or country of incorporation as L3.
Is Purple Biotech profitable?
Purple Biotech Ltd. reported net income of $17.8 million for the fiscal year ended Dec 31, 2021, per its annual report to the SEC.
What is the latest Purple Biotech (PPBT) stock news?
Our latest story on Purple Biotech, dated May 20, 2026: "Purple Biotech files $200,000,000 replacement shelf, ATM limited to $824,331". The F-3 caps the Wainwright ATM at $824,331 because the public float is below $75.0 million. The filing puts the float at $4.9 million, and the ADS last traded at $3.78 on May 18, 2026. Source.
Is Purple Biotech at risk of delisting?
Our latest listing story, dated Mar 17, 2026: "Purple Biotech regains Nasdaq minimum bid price compliance". The ADSs held a closing bid of $1.00 or more for at least 10 consecutive business days, reached on March 13, 2026. The company is now compliant with applicable listing standards. Source.
Is Purple Biotech a smaller reporting company?
SEC records list Purple Biotech Ltd.'s filer category as: Non-accelerated filer.
Where is Purple Biotech headquartered?
SEC records list its business address as 4 OPPENHEIMER STREET, REHOVOT, Israel, 7670104.
Investor discussion: Purple Biotech
Members talk about Purple Biotech (PPBT). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at Purple Biotech, newest first. Each line links the filing it comes from.
Financings
Set up an at-the-market program to sell shares over time. SEC Form F-3. Source
Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open TASE:PPBT on TradingView.
SEC filings and registration
SEC name
Purple Biotech Ltd.
CIK
1614744
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
PPBT (Nasdaq)
State or country of incorporation
L3
Fiscal year ends
December 31
Filer category
Non-accelerated filer
Business address
4 OPPENHEIMER STREET, REHOVOT, Israel, 7670104
Phone
97239333121
Shares outstanding
1,858,911,801 as of 2025-12-31 (20-F filed 2026-03-19)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
Purple Biotech Ltd. is a public biotech or pharmaceutical company listed on TASE under the ticker PPBT, recorded under Israel. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio